Oryzon Genomics (ORY.MC) traded down -1.19 % during a 24 hours period ending at 04:21 PM Central Europe on Monday 26th. One Oryzon Genomics stock can currently be bought for about EUR 2.51 on popular exchanges. Current supply of Oryzon Genomics stocks is 82 mn. Oryzon Genomics has a current market capitalization of EUR 204.9 mn and approximately EUR 308.6 k worth of Oryzon Genomics was traded on exchanges in the last 24 hours. Since last month end, Oryzon Genomics has traded -8.42 % down. Simple moving average of last 200 days is at EUR 2.91. The highest price of past 52 weeks was recorded at EUR 3.74 on 10/31/2025. 52 weeks low was at EUR 2.48 on 10/13/2026.

Here is how related stocks have performed in the past 24 hours:

  • Atrys Health (ATRY.MC) traded flat 0 % and now trades at EUR 2.68. Current market capitalisation for Atrys Health is EUR 198.1 mn.

  • Indexa Capital (INDXA.MC) traded down -2.56 % and now trades at EUR 15.2. Current market capitalisation for Indexa Capital is EUR 220.9 mn. Current price/earnings ratio for Indexa Capital is 67.77.

  • Laboratorio Reig Jofre (RJF.MC) traded flat 0 % and now trades at EUR 2.55. Current market capitalisation for Laboratorio Reig Jofre is EUR 212.6 mn. Laboratorio Reig Jofre has a current price to earnings ratio of 32.29.

  • Knowmad Mood (ATSI.MC) traded down -1.05 % and now trades at EUR 3.76. Current market capitalisation for Knowmad Mood is EUR 189 mn. Knowmad Mood has a current price to earnings ratio of 17.21.

  • Ecoener (ENER.MC) traded down -0.29 % and now trades at EUR 3.26. Ecoener has a market capitalisation of EUR 192.9 mn. Ecoener has a current price to earnings ratio of 45.13.

About Oryzon Genomics

Oryzon Genomics SA is a clinical stage biopharmaceutical company based in Barcelona, Spain. The company, founded in 2000, specializes in discovering and developing epigenetic therapies to treat oncology and neurodegenerative diseases. Its product candidates include ORY-1001, an oncology product in Phase I/IIA clinical trial for treating acute leukemia disease, and ORY-2001, a dual LSD1 and MAO-B inhibitor in Phase IIA clinical trial for multiple sclerosis, Alzheimer’s disease, and other neurodegenerative diseases. Additionally, the company is developing ORY-3001, a selective LSD1 inhibitor, in the preclinical stage for the treatment of non-oncological diseases. Oryzon Genomics SA also has additional programs in other cancer indications.